CO2021010698A2 - Formulaciones agradables al paladar - Google Patents

Formulaciones agradables al paladar

Info

Publication number
CO2021010698A2
CO2021010698A2 CONC2021/0010698A CO2021010698A CO2021010698A2 CO 2021010698 A2 CO2021010698 A2 CO 2021010698A2 CO 2021010698 A CO2021010698 A CO 2021010698A CO 2021010698 A2 CO2021010698 A2 CO 2021010698A2
Authority
CO
Colombia
Prior art keywords
animal
soft
chewable
flavor improver
veterinary
Prior art date
Application number
CONC2021/0010698A
Other languages
English (en)
Inventor
Paramjit Singh
Debendra Kumar Panda
Jeffrey Ellis Price
Atul Chhagan Badhan
Nicholas Finn Cunningham
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2021010698A2 publication Critical patent/CO2021010698A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención está dirigida a una composición blanda y masticable que comprende o contiene una cantidad terapéuticamente efectiva de un agente activo veterinario, preferentemente un inhibidor de JAK; un mejorador del sabor con base animal, un mejorador del sabor con base no animal, un modificador del sabor, y al menos un excipiente aceptable en la veterinaria que se selecciona de un grupo que consiste en un desintegrador, aglutinante, lubricante, humectante, y deslizante; y en la que la tableta blanda y masticable se comprime con una compresora de tabletas giratoria; y métodos para tratar o prevenir el cáncer, asma, dermatitis atópica, enfermedades autoinmunes, prurito asociado con la dermatitis alérgica, alergias, y enfermedad respiratoria crónica en un animal.
CONC2021/0010698A 2019-02-20 2021-08-13 Formulaciones agradables al paladar CO2021010698A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962807871P 2019-02-20 2019-02-20
PCT/US2020/018762 WO2020172232A1 (en) 2019-02-20 2020-02-19 Palatable formulations

Publications (1)

Publication Number Publication Date
CO2021010698A2 true CO2021010698A2 (es) 2021-08-30

Family

ID=69960719

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0010698A CO2021010698A2 (es) 2019-02-20 2021-08-13 Formulaciones agradables al paladar

Country Status (16)

Country Link
US (1) US20220062287A1 (es)
EP (1) EP3927315A1 (es)
JP (1) JP7442540B2 (es)
KR (1) KR20210114978A (es)
CN (1) CN113438941A (es)
AU (1) AU2020224102C1 (es)
BR (1) BR112021016480A2 (es)
CA (1) CA3127621C (es)
CL (1) CL2021002192A1 (es)
CO (1) CO2021010698A2 (es)
EC (1) ECSP21059181A (es)
IL (1) IL285078A (es)
MA (1) MA55027A (es)
MX (1) MX2021010066A (es)
UA (1) UA126843C2 (es)
WO (1) WO2020172232A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202122077A (zh) * 2019-09-06 2021-06-16 美商拜耳保健責任有限公司 適口軟咀嚼物
US20210068425A1 (en) * 2019-09-06 2021-03-11 Bayer Healthcare Llc Palatable granular veterinary compositions
WO2023198476A1 (en) * 2022-04-15 2023-10-19 Krka, D.D., Novo Mesto Soft chewable veterinary dosage form
JP7355175B1 (ja) 2022-07-25 2023-10-03 フジテック株式会社 エレベータのブレーキ制動能力検査方法及びブレーキ制動能力検査装置
FR3138315A1 (fr) 2022-07-27 2024-02-02 Virbac Produit à usage vétérinaire et procédé pour sa fabrication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623976B1 (fr) * 1987-12-08 1994-02-25 So Ge Val Comprime pour animal domestique
JP2004536826A (ja) 2001-06-21 2004-12-09 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な薬剤組成物
EP2314171B1 (en) 2002-08-13 2019-11-13 Intervet International BV Compositions and process for delivering an additive
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US20070128251A1 (en) 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) * 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
WO2008030469A2 (en) 2006-09-07 2008-03-13 Merial Limited Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
WO2014033230A1 (fr) 2012-08-31 2014-03-06 Friulchem Spa Compositions pour administration orale aux animaux, leurs procedes d'obtention et leurs utilisations
AU2012307656B2 (en) * 2011-09-15 2016-07-07 Friulchem Spa Compositions for oral administration to animals, production methods thereof and uses of same
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
DK2925305T3 (en) 2013-12-04 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan.
JP2017533959A (ja) 2014-11-03 2017-11-16 ゾエティス・サービシーズ・エルエルシー 嗜好性が高く咀嚼可能な獣医学的な組成物
WO2017106812A1 (en) 2015-12-19 2017-06-22 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations

Also Published As

Publication number Publication date
EP3927315A1 (en) 2021-12-29
CA3127621C (en) 2024-05-14
NZ779157A (en) 2023-10-27
AU2020224102A1 (en) 2021-08-19
ECSP21059181A (es) 2021-11-30
JP7442540B2 (ja) 2024-03-04
BR112021016480A2 (pt) 2021-10-13
AU2020224102B2 (en) 2022-09-08
WO2020172232A1 (en) 2020-08-27
KR20210114978A (ko) 2021-09-24
CL2021002192A1 (es) 2022-04-01
JP2022521245A (ja) 2022-04-06
US20220062287A1 (en) 2022-03-03
CA3127621A1 (en) 2020-08-27
MA55027A (fr) 2021-12-29
MX2021010066A (es) 2021-09-21
IL285078A (en) 2021-09-30
CN113438941A (zh) 2021-09-24
AU2020224102C1 (en) 2023-03-16
UA126843C2 (uk) 2023-02-08

Similar Documents

Publication Publication Date Title
CO2021010698A2 (es) Formulaciones agradables al paladar
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
CR20190212A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BRPI0508561A (pt) 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
JP2014505733A5 (es)
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
CR20210587A (es) Inhibidores de molécula pequeña de quinasa inductora de nf-kb
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
UY37577A (es) Dihidroimidazopiridindionas sustituidas
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
MX2022000960A (es) Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.
WO2015081319A3 (en) Activity enhancing curcumin compositions and methods of use
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
BR112014031706A2 (pt) composição farmacêutica oral; forma de composição farmacêutica oral; método de redução de efeito de alimento de itraconazol em um indivíduo; método de redução de variabilidade em um mesmo indivíduo de itraconazol; método de redução de variabilidade entre indivíduos de itraconazol; método de tratamento de onicomicose; método de tratamento de uma doença ou afecção e método de tratamento de câncer